Nemesis Bioscience Ltd has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established safe generic antibiotics to be effective again. The company has proven in the laboratory that its “Nemesis SymbioticsÓ convert antimicrobial resistant (AMR) bacteria to antibiotic sensitivity and also prevent bacteria from acquiring AMR – opening the possibility of protecting patients pre-operatively, or even pre-admission, to lower the risks of subsequent AMR infection.
To date, delivery systems into target bacteria have been developed for these Nemesis SymbioticsÓ using different vehicles for either treatment or protection. A single delivery method for both treatment and protection in a clinical setting is essential for clinical utility and economic feasibility.
The company has now invented such a delivery mechanism – TransmidsÓ that can be used clinically in the main focus areas of overcoming and preventing AMR without needing separate delivery mechanisms. However, the unique properties of TransmidsÓ also may make them ideal for use in existing synthetic biology and industrial microbiology applications where manipulation of bacterial genetics is fundamental – for example, the microbial production of biochemicals, biofuels and therapeutics.
The CEO of Nemesis, Dr Frank Massam commented, “This Smart Award will help us to efficiently evaluate and develop our new TransmidÓ technology not only for the clinical delivery of our range of therapeutics but also for economically important synthetic biology applications.”
____________________________________________